Ocular angiostatic agents

Bibliography

• LEE P, WANG CC, ADAMIS AP: Ocular neovasculariza- tion,: an epidemiologic review. Sant. Ophthalmol. (1998) 43:245–269.
   Google Scholar
• ••Excellent review on ocular neovascular diseases.
   Google Scholar
• AIELLO LP, BURSELL SE, CLERMONT A et al: Vascular endothelial growth factor-Induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective p-isoformsele-ctive inhibitor. Diabetes (1997) 46:1473–1480.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Tumor angiogenesis: therapeutic implica-tions. N Engli. Med. (1971) 285(20:1182–1186.
   PubMed Web of Science ®Google Scholar
• •Excellent introduction to theory and potential treatment of angiogenesis.
   Google Scholar
• BROOKS PC, SILLETTI S, VON SCHALSCHA TL, FRIEDLANDER, M, CHERESH DA: Disruption of angiogenesis by PEX, a noncatalytic met alloproteinase fragment with integrin binding activity. Cell (1998) 92:391–400.
   PubMed Web of Science ®Google Scholar
• DAWSON DW, VOLPERT OV, GILLIS P et al.: Pigmentepithelium-derived factor: a potent inhibitor of angiogenesis. Science (1999) 285:245–248.
   PubMed Web of Science ®Google Scholar
• KIMURA H, SAKAMOTO T, HINTON DR et al.: A newmodel of subretinal neovascularization in the rabbit. Invest. Ophthalmol. Vis. Sci. (1995) 36:2110–2119.
   PubMed Web of Science ®Google Scholar
• CLARK AF, MELLON J, LI X-Y et al: Inhibition of intrao-cular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest. Ophthalmol. Vis. Sci. (1999) 40(9):2158–2162.
   PubMedGoogle Scholar
• ROBINSON GA, AIELLO LM: Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow. InL Ophthalmol Clin. (1998) 8(2):89–102.
   Google Scholar
• ••Excellent review on ocular factors that iduceneovascularisation.
   Google Scholar
• AIELLO LP, AVERY RL, ARRIGG PG et al.: Vascularendothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl. J. Med. (1994) 331:1480–1487.
   PubMed Web of Science ®Google Scholar
• SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascularendothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359:843–845.
   PubMed Web of Science ®Google Scholar
• WARREN RS, YUAN H, MATLI MR, FERRARA N, DONNERDB: Induction of vascular endothelial growth factor by insulin-like growth Factor I in colorectal carcinoma. J. Biol. Chem. (1996) 271:29483–294.
   PubMed Web of Science ®Google Scholar
• ACHEN MG, STACKER SA: The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int. J. Exp. Path. (1998) 79:255–265.
   PubMedGoogle Scholar
• •Good review on the role of VEGF in angiogenesis.
   Google Scholar
• KVANTA A, ALGVERE PV, BERGLIN L, SEREGARD S: Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. (1996) 37:1929–1934.
   PubMed Web of Science ®Google Scholar
• MILLER J, ADAMIS A, SHIMA DEAL: Vascular endothelialgrowth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. (1994) 145:574–584.
   PubMed Web of Science ®Google Scholar
• YI X, OGATA N, KOMADA M et al: Vascular endothelialgrowth factor expression in choroidal neovasculariza-tion in rats. Graefe's Arch. Clin. Exp. Ophthalmol. (1997) 235 (5):313–319.
   PubMed Web of Science ®Google Scholar
• WADA M, OGATA N, OTSUJI T, UYAMA M: Expression ofvascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr. Eye Res. (1999) 18(3)203–213.
   Google Scholar
• SHIMA DT, ADAMIS AP, FERRARA N et al: Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol. Med. (1995) 1(2):182–193.
   PubMed Web of Science ®Google Scholar
• POURNARAS CJ, MILLER JW, EVANGELOS S et al.: Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch. Ophthalmol. (1997) 115:1553–1558.
   PubMedGoogle Scholar
• ROBBINGS SG, CONAWAY JR, FORD BL, ROBERTO KA, PENN JS: Detection of vascular endothelial growth factor (VEGF) protein in vascular and non-vascular cells of the normal and oxygen-injured rat retina. Growth Factors (1997) 14:229–241.
   PubMedGoogle Scholar
• AIELLO LP, PIERCE EA, FOLEY ED et al.: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA (1995) 92(23):10457–10461.
   PubMed Web of Science ®Google Scholar
• ADAMIS AP, SHIMA DT, TOLENTINO MJ et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. (1996) 114:66–71.
   PubMed Web of Science ®Google Scholar
• PREST LG, CHEN H, O'CONNOR SJ et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593–4599.
   PubMedGoogle Scholar
• KIM JJ, LI B, WINER J et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth factor in vivo. Nature (1993) 362:841–844.
   PubMed Web of Science ®Google Scholar
• EATON BE: The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets. Curr. Opin. Chem. Biol. (1997) 1:10–16.
   PubMed Web of Science ®Google Scholar
• GREEN LS, JELLINEK D, BELL C et al.: Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem. Biol. (1995) 2:683–695.
   PubMed Web of Science ®Google Scholar
• PATEL DJ: Structural analysis of nucleic acid aptamers. Curr. Opin. Exp. Biol. (1997) 1:32–46.
   PubMed Web of Science ®Google Scholar
• ROBINSON GS, PIERCE EA, ROOK SL, FOLEY E, WEBB R, SMITH LEH: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. (1996) 93:4851–4856.
   PubMed Web of Science ®Google Scholar
• KE L, FUEYO J, CHEN X et al.: A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int. J. Oncol. (1998) 12:1391–1396.
   PubMed Web of Science ®Google Scholar
• DRENSER KA, TIMMERS AM, HAUSWIRTH WW, LEWIN AS: Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa. Invest. Ophthalmol Vis. Sci. (1998) 39:681–689.
   PubMed Web of Science ®Google Scholar
• DUPONT E, SAVARD PE, JOURDAIN C et al.: Antiangio-genic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J. Cutan. Med. Surg. (1998) 2(3):146–152.
   PubMedGoogle Scholar
• SEPHAN CC, CHANG KC, LEJEUNE W et al.: Role for heparin-binding growth factors in glucose-induced vascular dysfunction. Diabetes (1998) 47(11):1171–1178.
   Google Scholar
• HANAHAN D: Signaling vascular morphogenesis andmaintenance. Science (1997) 277:48–60.
   PubMed Web of Science ®Google Scholar
• HAYASHI A, KOROMA BM, IMAI K, DE JUAN EJR: Increase of protein tyrosine phosphorylation in rat retina after ischemia-reperfusion injury. Invest. Ophthalmol Vis. Sci. (1996) 37(10:2146–2156.
   PubMedGoogle Scholar
• BULLARD LE, ROBERTO KA, FORD BL, PENN JS: Inhibi-tion of retinal neovascularization by intravitreal herbimycin A in a rat model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. (1997) 38(4) :S610–S610.
   Google Scholar
• STRAWN LM, MCMAHON G, APP H et al: Flk-1 as a target for tumor growth inhibition. Cancer Res. (1996) 56:3540–3545.
   PubMed Web of Science ®Google Scholar
• OZAKI H, SEO MS, OZAKI K, YAMADA H, YAMADA E, HOFMANN F: Blockage of VEGF receptor tyrosine kinase activity inhibits physiologic and pathologic neovascularization (NV) in the retina. Invest. Ophthalmol. Vis. ScL (1999) 40(4):S619–S619.
   Google Scholar
• SEO MS, KWAK N, OZAKI H et al.: Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. J. Pathol. (1999) 154:1743–1753.
   PubMed Web of Science ®Google Scholar
• BREIER G, DAMERT A, PLATE KH, RISAU W: Angiogenesis in embryos and ischemic diseases. Thromb. Haemost. (1997) 78(0:678–683.
   PubMedGoogle Scholar
• ASAHARA T, CHEN D, TAKAHASHI T et al: Tie2 receptor ligands, angiopoietin-1 and gngiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. (1998) 83:233–240.
   PubMed Web of Science ®Google Scholar
• DAVIS D, ALDRICH TH, JONES PF et al.: Isolation of angiopoietin-1, a ligand for the TIE receptor, by secretion-trap expression cloning. Cell (1996) 87:1161–1169.
   PubMed Web of Science ®Google Scholar
• SURI C, JONES PF, PATAN S et al.: Requisite role of angiopoietin-1, a ligand for the TIE receptor, during embryonic angiogenesis. Cell (1996) 87:1171–1180.
   PubMed Web of Science ®Google Scholar
• XIA P, INOGUCHI T, KERN TS, ENGERMAN RL, OATES PJ, KING GL: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes (1994) 43:1122–1129.
   PubMed Web of Science ®Google Scholar
• BURSELL S-E, TAKAGI C, CLERMONT A et al.: Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest. Ophthalmol. Vis. ScL (1997) 38:2711–2720.
   PubMedGoogle Scholar
• JIROUSEK MR, GILLIG JR, GONZALEZ CM et al.: (5)-13-[(Dimethylamino)methyl]-10,11,14,15-tetra hydro-4,9:16,21-dimetheno-1H,1311-dibenzo[e,k] pyrrolo [3,4, 13]- oxadiazacyclohexadece ne-1, 3 (211) - dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C. J. Med. Chem. (1996) 39(14):2664–2671.
   PubMedGoogle Scholar
• ISHII H, JIROUSEK MR, KOYA D et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC inhibitor. Science (1996) 272:728–731.
   PubMed Web of Science ®Google Scholar
• DANIS RP, BINGAMAN DP, JIROUSEK M, YANG Y: Inhibi-tion of intraocular neovascularization caused by retinal, ischemia in pigs by PKCB inhibition with LY333531. Invest. Ophthalmol. Vis. Sci. (2000) 39(1):171–179.
   Google Scholar
• RAK J, MITSUHASHI Y, BAYKO L et al.: Mutant rasoncogenes upregulate VEGFNPE expression: implica-tions for induction and inhibition of tumor angiogene-sis. Cancer Res. (1995) 55 :4575–4580.
   PubMed Web of Science ®Google Scholar
• KIM HA, LING B, RATNER N: Nf7-Deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol. Cell. Biol. (1997) 2:862–872.
   Google Scholar
• LEONARD DM: Ras farnyesyltransferase: a new therapeutic agent. J. Med. Chem. (1997) 40(19)2971–2990.
   Google Scholar
• HAMBY JM, CONNOLLY CJC, SCHROEDER MC et al.: Structure-activity relationships for a novel series of pyrido[2,3-c]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. (1997) 40:2296–2303.
   PubMedGoogle Scholar
• MOHAMMADI M, FROUM S, HAMBY JM et al.: Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. (1998) 17(20)5896–5904.
   Google Scholar
• PANEK RL, LU GH, KLUTCHKO SR et al.: In vitro pharma-cological characterization of PD 166285, a new nanamolar potent and broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. (1997) 283(3):1433–1444.
   PubMedGoogle Scholar
• PANEK RL, LU GH, DAHRING TK et al: In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J. Pharmacol. Exp. Ther. (1998) 286(0569–577.
   PubMed Web of Science ®Google Scholar
• WIEDEMANN P: Growth factors in retinal diseases:proliferative vitreoretinopathy, proliferative diabetic retinopathy and retinal degeneration. Surv. Ophthalmol (1992) 30(5):373–384.
   Google Scholar
• ADAMS DA, RAND RW, ROTH NH, DASHE AM, GIPSTEIN RM, HEUSER G: Hypophysectomy in diabetic retino-pathy. the relationship between the degree of pituitary ablation and ocular response. Diabetes (1974) 23 (8):698–707.
   Google Scholar
• JONES J, CLEMMONS D: Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. (1995) 16:3–34.
   PubMed Web of Science ®Google Scholar
• BURREN CP, BERKA JL, EDMONDSON SR, WERTHER GA,BATCH JA: Localization of mRNAs for insulin-like growth Factor I (IGFO, IGFI receptor and IGF binding proteins in rat eye. Invest. Ophthalmol. Vis. Sci. (1996) 37:1459–1468.
   PubMed Web of Science ®Google Scholar
• MORIARTY P, BOULTON M, DICKSON A, MCLEOD D: Production of IGF-I and IGF binding proteins by retinal cells in vitro. Br. J. Ophathamol. (1994) 78:638–642.
   PubMed Web of Science ®Google Scholar
• GRANT MB, MAMES RN, FITZGERALD C, ELLIS EA,ABOUFREIKHA M, GUY J: Insulin-like growth Factor I acts as an angiogenic agent in rabbit cornea and retina: comparative, studies with basic fibroblast growth factor. Diabetologia (1993) 36:282–291.
   PubMed Web of Science ®Google Scholar
• AVERBUKH E, WEISS O, HALPERT M et al.: Gene expres-sion of insulin-like growth-factor-I, its receptor and binding proteins in retina under hypoxic conditions. Metabolism (2000) 47:1331–1336.
   Google Scholar
• PUNGLIA RS, LU M, HSU J et al: Regulation of vascular endothelial growth factor expression by insulin-like growth Factor I. Diabetes (1997) 46:1619–1626.
   PubMed Web of Science ®Google Scholar
• SMITH LEH, KOPCHICK JJ, CHEN W et al.: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science (1997) 276:1706–1708.
   PubMed Web of Science ®Google Scholar
• BINGAMAN DP, DANIS RP, LEE WH, GRANT MB, WARREN RS: Increased vitreous VEGF levels precede IGFI system activation in the pig model of ocular angiogenesis induced via retinal ischemia. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):S367–5367.
   Google Scholar
• DANIS RP, BINGAMAN DP: Insulin-like growth factor-1 retinal microangiography in the pig eye. Ophthal-mology (1997) 104: 1661-1669.
   Google Scholar
• BOULTON M, GREGOR Z, MCLEOD D et al.: Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br. J. Ophathamol. (1997) 81:228–233.
   PubMed Web of Science ®Google Scholar
• WALDBILLIG RJ, JONES BE, SCHOEN TJ et al: Vitreal insulin-like growth factor binding proteins (IGEBPs) are increased in human and animal diabetes. Curr. Eye Res. (1994) 13:536–546.
   Google Scholar
• MYER-SCHWICKERATH R, PFEIFFER A, BLUM WF et al:Vitreous levels of the insulin-like growth factors land II and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. J. Clin. Invest. (1993) 92:2620–2625.
   PubMedGoogle Scholar
• DEMIR T, CELIKER UO, KUKNER A, MOGULKOC R, CELEBIS, CELIKER H: Effect of Octreotide on experimental corneal neovascularization. Arch. Ophthalmol. Scand. (1999) 77(4)386–390.
   Google Scholar
• LUETTKE B, LANG GE, BOEHM BO, LANG GK: Influenceof a somatostatin analogue on the course of persisting proliferative diabetic retinopathy after laser treatment. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):
   Google Scholar
• MALLET B, VIALETTES B, HAROCHE S et al.: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes Metab. (1992) 18(6):438–444.
   Web of Science ®Google Scholar
• ROBERTSON JE, WESTRA I, WOLTERING EA et al.: Intravitreal injection of octreotide acetate. J. Ocular Pharmcol. Ther. (1997) 13(2):171–177.
   PubMedGoogle Scholar
• GOA KL, HARIA M, WILDE MI: Lisinopril. a review of its pharmacology and use in the management of the complications of diabetes mellitus. Drugs (1997) 53 (6):1081–1105.
   Google Scholar
• CHATURVEDI N, SJOLIE AK, STEPHENSON JM et al.: The effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. Lancet (1998) 35i:28–31.
   Google Scholar
• WILLIAMS B: Angiotensin II, VEGF and diabetic retino-pathy. Lancet (1998) 35i:837–838.
   Google Scholar
• ZICHE M, MAGLIONE D, RIBATTI D et al.: Placenta growth factor-1 is chemotactic, mitogenic and angiogenic. Lab. Invest. (1997) 76(4):517–531.
   PubMed Web of Science ®Google Scholar
• KHALIQ A, FOREMAN D, AHMED A et al.: Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab. Invest. (1998) 78(1):109–116.
   PubMed Web of Science ®Google Scholar
• PEPPER M, MONTESANO R: Proteolytic balance and capillary morphogenesis. Cell Differ. Dev. (1990) 32:319–328.
   PubMedGoogle Scholar
• DAVIS GE, CAMARILLO CW: Regulation of endothelialcell morphogenesis by integrins, mechanical forces and matrix guidance pathways. Exp. Cell Res. (1995) 216:113–123.
   PubMed Web of Science ®Google Scholar
• •Good overview of the role of integrins in angiogenesis.
   Google Scholar
• WOJTOWICZ-PRAGA SM, DICKSON RB, HAWKINS MJ: Matrix met alloproteinase inhibitors. Invest. New Drugs (1997) 15:61–75.
   PubMed Web of Science ®Google Scholar
• •Good review of MMP inhibitors.
   Google Scholar
• MOSES MA: The regulation of neovascularization by matrix, met alloproteinases and their inhibitors. Stem Cells (2000) 15:180–189.
   Google Scholar
• •Good review on the role of MMPs and MMP inhibitors in neovascularisation.
   Google Scholar
• CLARK AF: New discoveries on the roles of matrix met alloproteinases in ocular cell biology and pathology. Invest. Ophthalmol. Vis. Sci. (1 9 9 8) 39 (13):2514–2514.
   Google Scholar
• STEEN B, SEJERSEN S, BERGLIN L, SEREGARD S, KVANTA A: Matrix met alloproteinases and met alloproteinase inhibitors in choroidal neovascular membranes. Invest. Ophthalmol Vis. Sci. (1998) 39(10:2194–2200.
   PubMedGoogle Scholar
• NELSON NJ: Inhibitors of angiogenesis enter Phase III testing. J. Nat. Cancer Inst. (1998) 90(13)960–963.
   Google Scholar
• WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M et al: Phase I trial of Marimastat, a novel matrix met alloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. (1 9 9 8) 16(0:2150-2156.
   Google Scholar
• ROSEMURGY A, HARRIS J, LANGLEBEN A, CASPER E, GOODE S, RASMUSSEN H: Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. Clin. Oncol. (1999) 22(3):247–252.
   PubMed Web of Science ®Google Scholar
• LOMBARD MA, WALLACE TL, KUBICEK MF et al.: Synthetic matrix met alloproteinase inhibitors and tissue inhibitor of met alloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-a receptors in a human colon adrenocarcinoma (Colo 205) cell line. Cancer Res. (1998) 58:4001–4007.
   PubMed Web of Science ®Google Scholar
• DRUMMOND AH, BECKETT P, BROWN PD et al.: Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY Acad. Sci. (1999) 878:228–235.
   PubMed Web of Science ®Google Scholar
• •Good review of MMP inhibitors.
   Google Scholar
• SANTOS O, MCDERMOTT CD, DANIELS RG, APPELT K Rodent, pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix met alloproeinases,. Clin. Exp. Metastasis (1997) 15:499–508.
   PubMed Web of Science ®Google Scholar
• NIESMAN MR, MCDERMOTT C, BREKKEN J, ZHANG KE,SHALINSKY DR, APPELT K: Ocular pharmacokinetics of AG3340, a selective inhibitor of matrix met alloprote-inases (MMPs) following repeated oral administration. Invest Ophthalmol. Vis. Sci. (1999) 40(4):S86.
   Google Scholar
• RIVERO ME, GARCIA CR, WILEY CA, KEEFE KS, APPELT K,FREEMAN WR: Evaluation of long-term effects of intrao-cular injections of AG3340, a selective matrix met allooproteinase inhibitor. Invest. Ophthalmol. Vis. Sci. (1999) 40(4):S172.
   Google Scholar
• RIVERO ME, GARCIA CR, HAGEDORN M et al: Intrao-cular properties of AG3340, a selective matrix met allo-proteinase inhibitor with antiangiogenic activity. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):S585.
   Google Scholar
• GARCIA CR, RIVERO ME, HAGEDORN M et al.: Efficacy of AG3340, a selective inhibitor of matrix met alloprote-inases in an animal model of retinal neovasculariza-tion. Invest. Ophthalmol. Vis. Sci. (1999) 40(4):S617.
   Google Scholar
• SHALINSKY DR, BREKKEN J, ZOU H et al.: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. NY Acad. ScL (1999) 878:236–270.
   PubMed Web of Science ®Google Scholar
• BECKETT RP: Recent advances in the field of matrixmet alloproteinase inhibitors. Exp. Opin. Ther. Patents (1996) 6(12):1305–1315.
   Google Scholar
• •Good review of MMP inhibitors.
   Google Scholar
• YAMAMOTO M, TSUJISHITA H, HORI N et al.: Inhibition of membrane-type 1 matrix met alloproteinase by hydroxamate inhibitors: An examination of the subsite pocket. J. Med. Chem. (1999) 41:1209–1217.
   Google Scholar
• LEVY DE, LAPIERRE F, LIANG W et al.: Matrix met allopro-teinase inhibitors: a structure activity study. J. Merl. Chem. (1998) 41:199–223.
   PubMed Web of Science ®Google Scholar
• •Good review of structure-activity relationship of MMP inhibitors.
   Google Scholar
• DAS A, MCLAMORE A, SONG W, MCGUIRE PG: Retinalneovascularization is suppressed with a matrix met alloproteinase inhibitor. Arch. Ophthalmol. (1999) 117:498–503.
   PubMed Web of Science ®Google Scholar
• STEINMANN-NIGGLI K, LUKES M, MARTI H-P: Ratmeangial cells and matrix met alloproteinase inhibitor: Inhibition of 72-kD Type IV collagenase (MMP-2) and of cell proliferation. J. Am. Soc. Nephrol. (1997) 8:395–405.
   PubMedGoogle Scholar
• PENN JS, ROBERTO KA, BULLARD LE: Inhibition ofretinal neovascularization by a broad spectrum matrix met alloproteinase inhibitor in an animal model of ROP. Invest. Ophthalmol Vis. Sci. (1999) 40(4):5618.
   Google Scholar
• ARMSTRONG D, UEDA T, ALJADA A et al.: Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-a, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis (1998) 2:93–104.
   PubMedGoogle Scholar
• CERRETTI DP, POINDEXTER K, CASTNER BJ et al: Charac-terization of the cDNA and gene for mouse tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and its location to mouse chromo-some 12 and human chromosome 2p25. Cytokine (1999) 11(8):541–551.
   PubMedGoogle Scholar
• CHERNEY RJ, WANG L, MEYER DT et al.: Macrocyclic hydroxamate inhibitors of matrix met alloproteinases and TNF-alpha production. Bioorg. Med. Chem. Lett. (1999) 9(9):1279–1284.
   PubMed Web of Science ®Google Scholar
• CRUM R, SZABO S, FOLKMAN J: A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science (1985) 230(4732):1375–1378.
   PubMedGoogle Scholar
• LI WW, CASEY R, GONZALEZ EM, FOLKMAN J: Angiostatic steroids potentiated by sulfated cyclodex-trins inhibit corneal neovascularization. Invest. Ophthalmol Vis. Sci. (1991) 32(10:2898–2905.
   PubMedGoogle Scholar
• PROIA AD, HIRAKATA A, MCINNES JS, SCROGGS MW, PARIKH I: The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp. Eye Res. (1993) 57(6)693–698.
   Google Scholar
• CLARK AF: AL-3789: a novel ophthalmic angiostatic steroid. Exp. Opin. Invest. Drugs (1999) 6(12):1867–1877.
   Google Scholar
• MCNATT LG, WEIMER L, YANNI J, CLARK AF: Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J. Ocular Pharmcol. Thera. (1999) 15(5):413–423.
   PubMed Web of Science ®Google Scholar
• BENEZRA D, GRIFFIN BW, MAFTZIR G, AHARONOV O, SHARIF NA, CLARK AF: Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascu-larization. Invest. Ophthalmol. Vis. Sci. (1997) 38:1954–1962.
   PubMed Web of Science ®Google Scholar
• PENN JS, RAJARATNAM VS, COLLIER RJ,CLARK AF The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. (2000) (Submitted)
   Google Scholar
• DEFALLER JM, Clark AF: A new pharmacological treatment for angiogenesis. In: Pterygium. Kugler Publications, The Hague, Netherlands (2000).
   Google Scholar
• FRIEDLANDER M, THEESFELD CL, SUGITA M et al.: Involvement of integrins avP3 and avBs in ocular neovascular diseases. Proc. Natl. Acad. ScL USA (1996) 93:9764–9769.
   PubMed Web of Science ®Google Scholar
• •Emphasises the importance of specific integrins in ocular neovascular diseases.
   Google Scholar
• FRIEDLANDER M, BROOKS PC, SHAFFER RW, KINCAID CM, VARNER JA, CHERESH DA: Definition of two angiogenic pathways by distinct av integrins. Science (1995) 270:1500–1502.
   PubMed Web of Science ®Google Scholar
• •Demonstrates involvement of two integrin pathways in angiogenesis.
   Google Scholar
• LUNA J, TOBE T, MOUSA SA, REILLY TM, CAMPOCHIARO PA: Antagonists of integrin avp3 inhibit retinal neovascularization in a murine model. Lab. Invest. (1996) 75(4):563–573.
   PubMed Web of Science ®Google Scholar
• NAUCK M, KARAKIULAKIS G, PERRUCHOUD AP, PAPAKONSTANTINOU E, ROTH M: Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. j Pharmacol (1998) 341(2-3):309–315.
   PubMed Web of Science ®Google Scholar
• ROTSCHILD T, NANDGAONKAR BN, YU K, HIGGINS RD: Dexamethasone reduces oxygen induced retinopathy in a mouse model. Pediatr. Res. (1999) 46(1):94–100.
   PubMedGoogle Scholar
• FLAXEL CJ, OWENS SL, MULHOLLAND B, SCHWARTZ SD, GREGOR ZJ: The use of corticosteroids for choroidal neovascularization in young patients. Eye (1998) 12:266–272.
   PubMed Web of Science ®Google Scholar
• CHALLA JK, GILLIES MC, PENFOLD PL, GYORY JF, HUNYOR AB, BILLSON FA: Exudative macular degenera-tion and intravitreal triamcinolone: 18 month follow up. Aust. NZ J. Ophthalmol. (1998) 26(4):277–281.
   PubMedGoogle Scholar
• O'REILLY MS, HOMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metasteses by a Lewis lung carcinoma. Cell (1994) 79(2):315–328.
   Google Scholar
• STACK MS, GATELY S, BAFETTI LM, ENGHILD JJ, SOFF GA: Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem. J. (1999) 340:77–84.
   PubMedGoogle Scholar
• MOSER TL, STACK MS, ASPLIN I et al.: Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA (1999) 96(6):2811–2816.
   PubMed Web of Science ®Google Scholar
• CAO Y, CHEN A, AN SSA, JI RW, DAVIDSON D, LLINAS M: Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem. (1997) 272(36)22924–22928.
   Google Scholar
• JI RW, BARRIENTAS LG, LLINAS M et al.: Selective inhibi-tion by Kringle 5 of human plasminogen on endothe-lial cell migration, an important process in angiogenesis. Biochem. Biophys. Res. Commun. (1998) 247 (2):414–419.
   PubMed Web of Science ®Google Scholar
• LU H, DHANABAL M, VOLK R et al.: Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem. Biophys. Res. Commun. (1999) 258(3)668–673.
   Google Scholar
• O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2):277–285.
   Google Scholar
• DHANABAL M, RAMCHANDRAN R, WATERMAN MJ et al: Endostatin induces endothelial cell apoptosis. J. Biol. Chem. (1999) 274(17):11721–11726.
   PubMed Web of Science ®Google Scholar
• HOHENESTER E, SASAKI T, OLSEN BR, TIMPL R: Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J (1998) 17(6):1656–1664.
   Google Scholar
• MOSES MA, WIEDERSCHAIN D, WU I et al.: Troponin I is present in human cartilage and inhibits angiogenesis. Proc. Natl. Acad. Sci. USA (1999) 96(6):2645–2650.
   PubMed Web of Science ®Google Scholar
• INGBER D, FUJITA T, KISHIMOTO S et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 348:555–557.
   PubMed Web of Science ®Google Scholar
• ISHIDA K, YOSHIMURA N, MANDAI M, HONDA Y: Inhibi-tory effect of TNP-470 on experimental choroidal neovascularization, in a rat model. Invest. Ophthalmol Vis. Sci. (1999) 40(7):1512–1519.
   PubMedGoogle Scholar
• KUSAKA M, SUDO K, FUJITA T et al.: Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun. (1999) 174(3):1070–1076.
   Google Scholar
• SIN N, MENG L, WANG MQ, WEN JJ: The anti-angiogenic agent fumagillin covalently binds and inhibits the mehtionine amionopeptidase, Met AP-2. Proc. Natl. Acad. Sci. (1997) 94(12)6099–6103.
   Google Scholar
• WERNERT N, STANJEK A, KIRIAKIDIS S et al.: Inhibition of angiogenesis in vivo by ets-1 transcription factor expression by antibiotic fumagillin. Angew. Chem. Int. Ed. (1999) 38(20:3228–3231.
   PubMedGoogle Scholar
• KENYON BM, BROWNE F, D'AMATO RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. (1997) 64(6):971–978.
   PubMed Web of Science ®Google Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91(9):4082–4085.
   PubMed Web of Science ®Google Scholar
• KRUSE FE, JOUSSEN AM, HINTON DR, BECKER R, VOLCKER HE: Thalidomide inhibits corneal angiogene-sis induced by vascular endothelial growth factor. Graefe's Arch. Ophthalomol. (1998) 236(6)461–466.
   Google Scholar
• VERHEUL HM, PANIGRAHY D, YUAN J, D'AMATO RJ: Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br. J. Cancer (1999) 79(0:114–118.
   PubMedGoogle Scholar
• OZAKI H, HAYASHI H, OSHIMA K: Angiogenin levels in the vitreous from patients with proliferative diabetic retinopathy. Ophthalmic Res. (1996) 28(6)356–360.
   Google Scholar
• SILLS AKJR, WILLIAMS JI, TYLER BM et al.: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. (1998) 58(13)2784–2792.
   Google Scholar
• BROOKS PC, MONTGOMERY AMP, ROSENFELD M et al.: Integrin av83 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79:1157–1164.
   PubMed Web of Science ®Google Scholar
• VOLPERT OV, WARD WF, LINGEN MW et al.: Captopril inhibits angiogenesis and slows the growth of experi-mental tumors in rats. J. Clin. Invest. (1996) 98(3)671–679.
   Google Scholar
• XIN X, YANG S, KOWALSKI J, GERRITSEN ME: Peroxi-some proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. (1999) 274(13):9116–9121.
   PubMed Web of Science ®Google Scholar
• TAKEHANA Y, KUROKAWA T, KITAMURA T et al.: Suppression of laser-induced choroidal neovasculari-zation by oral tranilast in the rat. Invest. Ophthalmol Vis. Sci. (1999) 40(2):459–466.
   PubMedGoogle Scholar
• MAISONPIERRE PC, SURI C, JONES PF et al.: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 277(532)55–60.
   Google Scholar
• UN P, BUXTON JA, ACHESON A et al: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. USA (1998) 95(15)8829–3334.
   Google Scholar
• UN P, POLVERINI P, DEWHIRST M, SHAN S, AO PS, ETERS K: Inhibition of tumor angiogenesis using soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. (1997) 100(8):2072–2078.
   PubMedGoogle Scholar
• OH H, TAKAGI H, SUZUMA K, OTANI A, MATSUMURA M, HONDA Y: Hypoxia and vascular endothelial growth factor selectively upregulate angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. (1999) 274 (22) :15732–15739.
   PubMed Web of Science ®Google Scholar
• OTANI A, TAKAGI C, OH H, KOYAMA S, MATSUMURA M, HONDA Y: Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. (1999) 40(9):1912–1920.
   PubMed Web of Science ®Google Scholar
• LYDEN D, YOUNG AZ, ZAGZAG D et al: Idl and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature (1999) 401:6
   Google Scholar
• METRIKIN DC, ANAND R: Intravitreal drug administra-tion with depot devices. Curr. Opin. Ophthalmol. (1994) 5 (3):21–29.
   PubMedGoogle Scholar
• MORITA Y, OHTORI A, KIMURA M, TOJO K: Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants. Biol. Pharm. (1998) 21(2):188–190.
   PubMed Web of Science ®Google Scholar
• RUBSAMEN PE, DAVIS PA, HERNANDEZ E, O'GRADY GE, COUSINS SW: Prevention of experimental proliferative vitreoretinopathy with biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol. (1994) 112 (3) :407–413.
   PubMed Web of Science ®Google Scholar
• MIYAMOTO H, OGURA Y, HASHIZOE M, KUNOU N, HONDA Y, IKADA Y: Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. (1997) 16(9):930–935.
   PubMed Web of Science ®Google Scholar
• ANAND R, NIGHTINGALE SD, FISH RH, SMITH TJ, ASHTON P: Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch. Ophthalmol. (1993) 1 1 1(2):223–227.
   Google Scholar
• MUSCH DC, MARTIN DF, GORDON JF, DAVIS MD, KUPPERMANN BD: Treatment of cytomegalovirus retinitis with sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl. J. Med. (1997) 337(2)83–90.
   Google Scholar